Opinion|Videos|July 24, 2024
Primary Progressive Multiple Sclerosis Treatment Landscape: Emerging Therapies
Key opinion leaders discuss the single FDA-approved option for primary progressive multiple sclerosis and emerging therapies under investigation for this MS subtype, examine the PERSEUS trial, and address concerns they anticipate with the potential approval of BTKis for MS patients and strategies for mitigating these concerns.
Advertisement
Episodes in this series
Video content above is prompted by the following questions:
- There is only one FDA-approved option for primary progressive multiple sclerosis. What emerging therapies are under investigation for this subtype of MS?
- Discuss the PERSEUS trial, which is evaluating tolebrutinib in primary progressive multiple sclerosis.
- What are the potential adverse effects of BTKis and how should they be monitored for and managed?
- What access concerns do you anticipate with the potential approval of BTKis for patients with MS, and how can they be mitigated?
- Discuss considerations of BTKis in oncology and how these may relate to MS.
Advertisement
Related to this article
The Autus Size-Adjustable Valve, which can be expanded as children grow, may reduce the need for repeat open-heart surgeries for congenital defects.
A scoping review of 15 studies found psoriasis prevalence markedly lower across 13 indigenous populations worldwide.
A traditional Medicare out-of-pocket (OOP) cap could reduce beneficiaries’ costs but increase annual federal spending by $39 billion to $96 billion.
A systemic sclerosis inception cohort and 17-study meta-analysis found a nearly 5-fold increase in lung cancer risk.
Medicare Advantage plans have varied motivations, strategies, and aspirations for addressing health-related social needs among home health beneficiaries, highlighting a need to expand the scope of supplemental benefits.
2026 Nobel Prize in Medicine honors optogenetics pioneers who turn algae light-sensing protein into neural switches, transforming brain mapping and enabling vision-restoration trials.
Medicare's Transforming Episode Accountability Model is projected to save $46.6 million by 2030, with safety-net hospitals potentially receiving the highest reconciliation payments.
A comparison of 2013 and 2022 data shows that cancer costs are not uniformly rising. Costs decreased for metastatic colorectal cancer but increased for both metastatic non–small cell lung cancer and multiple myeloma.
Advertisement
Advertisement
Trending on AJMC
1
Systemic Sclerosis Linked to Dramatic Rise in Lung Cancer Risk
2
FDA Approves First Heart Valve to Keep Pace With Children's Growth
3
Psoriasis Is Much Rarer in Indigenous Groups Worldwide
4
Traditional Medicare OOP Cap Could Lower Costs, Raise Federal Spending
5